Robert Meissner

Robert Meissner has held various leadership roles in the field of chemical sciences. Robert is currently the Senior Vice President and Head of Chemical Sciences at Blueprint Medicines since July 2022. Prior to this, they were the Vice President and Head of Chemical Sciences at the same company from May 2020 to July 2022. Before joining Blueprint Medicines, Meissner worked at Biogen as the Senior Director and Head of Medicinal and Computational Chemistry from May 2014 to May 2020. During their time at Biogen, they significantly expanded the Medicinal Chemistry department and led the discovery of drugs for neurodegenerative diseases. Robert also has extensive experience at Merck, where they served as the Director of Medicinal Chemistry from May 2005 to April 2014. Meissner made notable contributions to the development of cognitive decline treatments and inflammatory disease treatments at Merck. Their career at Merck began in 1996, where they started as a Senior Research Chemist and later became a Senior Research Fellow. During this time, they co-invented a selective androgen receptor modulator and led a discovery chemistry group.

Robert Meissner completed a Postdoctoral Fellowship at the Massachusetts Institute of Technology from 1993 to 1996. Before that, they obtained a Doctor of Philosophy (PhD) in Organic Chemistry from the University of Virginia between 1989 and 1993. Robert received their undergraduate education from Bucknell University, where they studied Chemistry from 1985 to 1989.